CAPR - CAPRICOR THERAPEUTICS, INC.
IEX Last Trade
14.005
0.180 1.285%
Share volume: 2,873
Last Updated: Thu 26 Dec 2024 04:29:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$13.82
0.18
1.30%
Fundamental analysis
22%
Profitability
25%
Dept financing
11%
Liquidity
50%
Performance
15%
Performance
5 Days
7.19%
1 Month
-25.56%
3 Months
35.49%
6 Months
201.94%
1 Year
214.83%
2 Year
298.01%
Key data
Stock price
$14.00
DAY RANGE
$13.56 - $13.98
52 WEEK RANGE
$3.80 - $23.40
52 WEEK CHANGE
$175.79
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Linda Marbán
Region: US
Website: capricor.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: capricor.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Capricor Therapeutics, Inc. focuses on the development of transformative cell and exosome-based therapeutics. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD) The company also develops CAP-2003 that is in pre-clinical development for the. treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.
Recent news